ArticleJournal of medical biochemistry2026
Biochemical indicators of inflammatory response in leukemia patients with picc-associated phlebitis: Evaluation of basic fibroblast growth factor combined with light therapy.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peripherally inserted central catheter (PICC)associated phlebitis is a common complication in leukemia treatment, closely related to inflammatory responses. Current standard management, primarily relying on catheter removal and anti-inflammatory drugs, often demonstrates insufficient efficacy in rapidly controlling inflammation, resolving symptoms, and preventing recurrence. Moreover, there is a notable lack of objective, biomarker-driven monitoring methods to guide and evaluate therapy. This study aimed to investigate the biochemical changes in key inflammatory markers - C-reactive protein (CRP), procalcitonin (PCT), erythrocyte sedimentation rate (ESR), and interleukin-6 (IL-6) - in patients with PICC-associated phlebitis, and to evaluate their value in monitoring the efficacy of basic fibroblast growth factor (bFGF) combined with light therapy, a novel approach proposed to address these limitations. Methods: A retrospective cohort of 65 leukemia patients with PICC-associated phlebitis was analyzed. Patients were divided into an intervention group (bFGF + light therapy, n=33) and a control group (standard care, n=32). Inflammatory markers (CRP, PCT, ESR, IL-6) were measured before and after 7 days of treatment using standardized laboratory assays. Phlebitis grading, visual analogue scale (VAS) pain scores, and EORTC QLQ-C30 quality of life scores were also assessed. Results: By day 7, the intervention group showed significantly greater reductions in CRP (69.9% vs 28.2%), PCT (71.2% vs 4.4%), ESR (69.7% vs 18.9%), and IL-6 (81.1% vs 14.5%) compared with controls (all P<0.001). These biochemical improvements paralleled reductions in phlebitis severity and pain, and correlated with enhanced quality of life scores. Conclusions: CRP, PCT, ESR, and IL-6 serve as sensitive biochemical indicators for evaluating treatment response in PICC-associated phlebitis. The findings highlight the clinical utility of these laboratory markers in monitoring therapeutic efficacy and suggest that bFGF combined with light therapy exerts significant anti-inflammatory effects in leukemia patients, offering a promising alternative to conventional strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.